A Phase 4 interventional study of Medicinal gas - oxygen (Nippon Gases 200 bar) and CPAP in Lung Resection Surgery and Anesthesia General, sponsored by Francisco Andres de la Gala. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Francisco Andres de la Gala · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Postoperative Complications with a site in Spain — 13 open to participants now, 15 under way, 1 of them phase 3. Postoperative Complications · Spain.
Among the 69 studies in Postoperative Complications with a site in Spain, this one is the 17th largest by planned enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 4, reaches primary completion later than 6 of the 14 other live ones, and was the 66th registered.
1,343 studies on the registry are indexed under Postoperative Complications; 314 are open to participants now.
Browse Postoperative Complications studies →13 of the 69 studies in Postoperative Complications with a site in Spain are open now. Recruiting first, the newest first:
University of Seville · Sites in Spain
Ages 18–80
Zealand Pharma · Sites in Spain, United States, Austria and 11 more countries
Ages 18–90
Carlos Alfredo Fraile Olivero, MD, PhD. · Sites in Spain
Ages 18+
Hospital Universitario de Gran Canaria Doctor Negrín · Sites in Spain
Ages 18+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 200 Postoperative Complications studies recruiting now, 126 (63%) set no upper age limit and 31 (16%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 177 is above the median of 113 across 773 interventional studies indexed under Postoperative Complications.
Median enrollment 178 across the 32 interventional studies, 400 across the 37 observational. Of the 41 that completed or were terminated, 3 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 69 have an industry lead sponsor. The 10 most frequent:
Francisco Andres de la Gala is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Francisco Andres de la Gala has 2 studies filed under Postoperative Complications — fewer than ten, so there is no comparison to draw.
5 of the studies in Postoperative Complications with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04973397Centre hospitalier de l'Université de Montréal (CHUM)Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study | 2026-12 |
| NCT04794582Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalPrevention of Incisional Hernia After Renal Transplantation | 2026-12 |
| NCT07461779Francisco Andres de la GalaEffect of Oxygen Administration in the Non-dependent Lung on Postoperative Complications After Lung Surgery | 2026-12-30 |
| NCT06732193Carlos Alfredo Fraile Olivero, MD, PhD.Fissios© and Postoperative Complications (FPoC Trial) | 2026-12-31 |
| NCT07771049Hospital Universitario La FeOpioid-Free Anesthesia in Colorectal Surgery, 2025 (OFA-CRC-2025) | 2027-07-20 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in Postoperative Complications with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to analyze the effectiveness of apneic oxygenation and CPAP applied to the non-dependent lung during pulmonary resection surgery in reducing inflammatory response, ischemia-reperfusion injury, and postoperative complications. We will conduct a randomized, controlled, and blinded study in 177 patients with three arms:
Inflammatory mediators in blood and in both lungs will be measured intraoperatively and 24 hours after surgery. Patients will be followed from hospital admission until discharge and again 30 days after surgery to evaluate the postoperative course, particularly the occurrence of complications according to the revised Clavien-Dindo classification for thoracic surgery, as well as other relevant clinical outcomes.
Surgical interventions, particularly lung resection, provoke a significant inflammatory response at both local and systemic levels, characterized by hyperemia and increased vascular permeability. Thoracic surgery requiring one-lung ventilation (OLV) leads to complications such as intraoperative hypoxemia and an exaggerated pulmonary inflammatory response, threatening patient stability. Hypoxemia-commonly defined as SpO2 \< 85-90% or PaO2 \< 60 mmHg-is frequent and increases the risk of complications such as arrhythmias, cognitive dysfunction, pulmonary hypertension, and renal failure, particularly in patients with comorbidities. The difficulty in defining a precise threshold for complications reflects that oxygen deprivation-related tissue hypoxia depends on the balance between oxygen supply and consumption, which is influenced by individual variables such as cardiovascular function and pre-existing conditions.
To mitigate hypoxemia during OLV, several strategies have been implemented. The most common are increasing FiO2 and applying continuous positive airway pressure (CPAP), which significantly improves arterial oxygenation. However, higher pressures may hinder surgical manipulation due to anatomical distortion. Currently, low-pressure CPAP (around 2 cmH2O) is recommended because it provides oxygenation benefits without interfering with the surgery, although clinical evidence remains limited. Apneic oxygenation has also been proposed: oxygen is administered without positive pressure, taking advantage of the fact that during apnea oxygen can diffuse into the alveoli down pressure gradients, sustaining arterial oxygenation even with collapsed lung regions. This technique can prolong safe apnea time, reduce hyperoxia risk, and maintain oxygenation while minimizing interference with surgical exposure.
Conversely, OLV triggers a strong inflammatory response caused by tissue injury, atelectrauma, volutrauma, and barotrauma in the dependent lung, along with oxidative stress damage in the non-ventilated lung. Prolonged exposure to high FiO2 contributes to lung injury through oxidative mechanisms similar to those in adult acute respiratory distress syndrome. Re-expansion of the collapsed lung after OLV also releases free radicals, exacerbating ischemia-reperfusion injury, especially in lung cancer patients who may have reduced antioxidant capacity. Activation of the NLRP3 inflammasome, stimulated by reactive oxygen species, promotes proinflammatory cytokine production, contributing to tissue damage, increased capillary permeability, and pulmonary edema, thereby raising the risk of postoperative respiratory failure.
Although advances have been made, evidence is limited regarding the impact of apneic oxygenation on reducing inflammation, oxidative stress, and postoperative complications in lung surgery. However, studies in other surgeries suggest this technique could decrease inflammatory markers and improve oxygenation without impairing surgical exposure. Therefore, this study aims to evaluate and compare the efficacy of apneic oxygenation and CPAP applied to the nondependent lung during lung resection surgery, focusing on reducing inflammatory response, ischemia-reperfusion injury, and postoperative complications, and thus providing evidence to improve perioperative strategies for these patients.
Hypothesis: Maintaining a continuous oxygen flow to the nondependent lung, with minimal pressure (CPAP) or none at all (apneic oxygenation), during OLV will reduce alveolar hypoxia in that lung, thereby attenuating ischemia-reperfusion-related lung injury and improving the postoperative course. Additionally, it will reduce the incidence of intraoperative hypoxemia and permit use of lower oxygen concentrations to the dependent lung, which may further improve prognosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oxygen therapy according to standard clinical practice. The nondependent lung (surgical) will be connected to ambient air by opening the lumen of the double-lumen tube (DLT) directed towards that lung
Procedure: Oxygen therapy according to standard clinical practice
Continuous positive airway pressure with 3-5 L/min oxygen and 2 cmH2O pressure delivered via a Mapleson system
Device: CPAP
A probe will be introduced through the lumen of the DLT to deliver a continuous flow of oxygen without any mechanism that generates airway pressure
Drug: Medicinal gas - oxygen (Nippon Gases 200 bar)
Medicinal gas, compressed. Oxygen 99.5% v/v
Continuous positive pressure
Ambient air connection
Postoperative complications
To compare the proportion of patients in each grade of the revised Clavien-Dindo classification for thoracic surgery across the three study groups
Time frame: Up to 30 days after intervention
Gas exchange and acid-base balance
To compare gas exchange and acid-base balance during the intraoperative period and during the first 24 hours postoperatively
Time frame: Intraoperative period and 24 hours
Degree of interference with surgical exposure (Surgeon Satisfaction Scale on Oxygen Therapy Interference, 1-5)
Assessed by the surgeon at the end of the procedure using the Surgeon Satisfaction Scale on Oxygen Therapy Interference, an ordinal 5-point scale: 1 = Surgery impossible (change O2 administration method required); 2 = Very difficult technique (no change in O2 administration required); 3 = Considerably more difficult than usual; 4 = Somewhat more difficult than usual; 5 = Similar to usual.
Time frame: Surgery duration; assessed at end of surgery
Incidence of postoperative pulmonary complications
To compare de incidence of postoperative pulmonary complications among the three study groups
Time frame: Up to 30 days after intervention
Special Care Units stay
To compare the length of stay in Special Care Units among the three study groups
Time frame: Up to 30 days after intervention
Readmisions to Special Care Units
To compare the number of readmissions to Special Care Units among the three study groups
Time frame: Up to 30 days after intervention
Hospital Stay
To compare the average hospital stay (measure in days) among the three study groups
Time frame: Up to 30 days after intervention
Hospital readmission
To compare hospital readmissions among the three study groups
Time frame: Up to 30 days after intervention
Inflammatory biomarkers in blood and bronchoalveolar lavages
To evaluate the inflammatory response measured in blood and bronchoalveolar lavages during the first 24 hours postoperatively in the three patient groups. Blood samples and bronchoalveolar lavages will be taken at the beginning of surgery, at the end of one-lung ventilation, and at 24 hours postoperatively
Time frame: Up to 24 hours after intervention
New molecules involved in oxidative stress
Identification of new molecules involved in oxidative stress: Plasma concentrations of oxidative stress markers (SOD, MDA, MPO, CP, ROS index, plasma thiols). All biochemical determinations will be performed by spectrophotometry using validated specific kits. Samples collected pre-intervention and at 2, 6 and 24 hours post-intervention.
Time frame: Up to 24 hours after intervention
Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.
Of 45 non-industry phase 4 interventional studies under Postoperative Complications, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 32. This study's planned 23 months is close to that.
Counting every sponsor, half of 46 studies reached it within 25 months; a quarter within 19 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Francisco Andres de la Gala